192 related articles for article (PubMed ID: 6652076)
21. Microsomal lipoamide reductase provides vitamin K epoxide reductase with reducing equivalents.
Thijssen HH; Janssen YP; Vervoort LT
Biochem J; 1994 Jan; 297 ( Pt 2)(Pt 2):277-80. PubMed ID: 8297331
[TBL] [Abstract][Full Text] [Related]
22. Characterization and purification of the vitamin K1 2,3 epoxide reductases system from rat liver.
Begent LA; Hill AP; Steventon GB; Hutt AJ; Pallister CJ; Cowell DC
J Pharm Pharmacol; 2001 Apr; 53(4):481-6. PubMed ID: 11341364
[TBL] [Abstract][Full Text] [Related]
23. Identification of a warfarin-sensitive protein component in a 200S rat liver microsomal fraction catalyzing vitamin K and vitamin K 2,3-epoxide reduction.
Lee JJ; Principe LM; Fasco MJ
Biochemistry; 1985 Dec; 24(25):7063-70. PubMed ID: 4084561
[TBL] [Abstract][Full Text] [Related]
24. Metabolism of vitamin K and vitamin K 2,3-epoxide via interaction with a common disulfide.
Lee JJ; Fasco MJ
Biochemistry; 1984 May; 23(10):2246-52. PubMed ID: 6733086
[TBL] [Abstract][Full Text] [Related]
25. Effect of warfarin on plasma and liver vitamin K levels and vitamin K epoxide reductase activity in relation to plasma clotting factor levels in rats.
Yamanaka Y; Yamano M; Yasunaga K; Shike T; Uchida K
Thromb Res; 1990 Jan; 57(2):205-14. PubMed ID: 2315885
[TBL] [Abstract][Full Text] [Related]
26. Formation of 3-hydroxy-2,3-dihydrovitamin K1 in vivo: relationship to vitamin K epoxide reductase and warfarin resistance.
Preusch PC; Suttie JW
J Nutr; 1984 May; 114(5):902-10. PubMed ID: 6726460
[TBL] [Abstract][Full Text] [Related]
27. B16 tumor cells contain a warfarin sensitive vitamin K1 2,3 epoxide reductase.
Uitendaal MP; Thijssen HH; Drittij-Reijnders MJ; Hoeijmakers MJ
Biochem Biophys Res Commun; 1986 Jun; 137(3):1015-20. PubMed ID: 3729947
[TBL] [Abstract][Full Text] [Related]
28. Conversion of vitamin K epoxide to hydroxyvitamin K by liver microsomes from warfarin-resistant rats.
Nutr Rev; 1983 Aug; 41(8):253-4. PubMed ID: 6355923
[No Abstract] [Full Text] [Related]
29. In vitro effect of beta-lactam antibiotics and N-methyltetrazolethiol on microsomal vitamin K epoxide reductase in rats.
Kawamoto K; Touchi A; Sugeno K; Matsubara T
Jpn J Pharmacol; 1988 Jun; 47(2):169-78. PubMed ID: 3199593
[TBL] [Abstract][Full Text] [Related]
30. Determination of the warfarin inhibition constant Ki for vitamin K 2,3-epoxide reductase complex subunit-1 (VKORC1) using an in vitro DTT-driven assay.
Bevans CG; Krettler C; Reinhart C; Tran H; Koßmann K; Watzka M; Oldenburg J
Biochim Biophys Acta; 2013 Aug; 1830(8):4202-10. PubMed ID: 23618698
[TBL] [Abstract][Full Text] [Related]
31. Relationship of dithiothreitol-dependent microsomal vitamin K quinone and vitamin K epoxide reductases inhibition of epoxide reduction by vitamin K quinone.
Preusch PC; Suttie JW
Biochim Biophys Acta; 1984 Mar; 798(1):141-3. PubMed ID: 6704420
[TBL] [Abstract][Full Text] [Related]
32. Vitamin K epoxide and quinone reductase activities. Evidence for reduction by a common enzyme.
Gardill SL; Suttie JW
Biochem Pharmacol; 1990 Sep; 40(5):1055-61. PubMed ID: 2390102
[TBL] [Abstract][Full Text] [Related]
33. Vitamin-K-dependent proteins in microsomes of primary Lewis lung tumors.
Wilson AC; Fasco MJ
Int J Cancer; 1986 Dec; 38(6):877-82. PubMed ID: 3793264
[TBL] [Abstract][Full Text] [Related]
34. The in vivo effects of acenocoumarol, phenprocoumon and warfarin on vitamin K epoxide reductase and vitamin K-dependent carboxylase in various tissues of the rat.
de Boer-van den Berg MA; Thijssen HH; Vermeer C
Biochim Biophys Acta; 1986 Oct; 884(1):150-7. PubMed ID: 3490277
[TBL] [Abstract][Full Text] [Related]
35. Is thioredoxin the physiological vitamin K epoxide reducing agent?
Preusch PC
FEBS Lett; 1992 Jul; 305(3):257-9. PubMed ID: 1299627
[TBL] [Abstract][Full Text] [Related]
36. Effect of N-ethylmaleimide on beef and rat liver vitamin K1 epoxide reductase.
Silverman RB; Nandi DL
J Enzyme Inhib; 1990; 3(4):289-94. PubMed ID: 2319331
[TBL] [Abstract][Full Text] [Related]
37. Co-purification of microsomal epoxide hydrolase with the warfarin-sensitive vitamin K1 oxide reductase of the vitamin K cycle.
Guenthner TM; Cai D; Wallin R
Biochem Pharmacol; 1998 Jan; 55(2):169-75. PubMed ID: 9448739
[TBL] [Abstract][Full Text] [Related]
38. Temporal variation in the effects of warfarin on the vitamin K cycle.
Soulban G; Labrecque G; Bélanger PM
Chronobiol Int; 1990; 7(5-6):403-11. PubMed ID: 2097073
[TBL] [Abstract][Full Text] [Related]
39. Warfarin resistance in a Chicago strain of rats.
Misenheimer TM; Suttie JW
Biochem Pharmacol; 1990 Nov; 40(9):2079-84. PubMed ID: 2242035
[TBL] [Abstract][Full Text] [Related]
40. A fibroblast cell culture model to study vitamin K metabolism and the inhibition of vitamin K epoxide reductase by known and suspected antagonists.
Ross PJ; Shearer MJ; Diplock AT; Schey SA
Br J Haematol; 1991 Feb; 77(2):195-200. PubMed ID: 2004021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
